Engineering IL-2 for immunotherapy of autoimmunity and cancer.
Nat Rev Immunol. 2022 Feb 25. doi: 10.1038/s41577-022-00680-w. Online ahead of print.
Nat Rev Immunol. 2022.
PMID: 35217787
Review.